EAM Investors’s Cytokinetics CYTK Stock Holding History

EAM Investors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.81M	Buy	+68,185	New	+$4.9M	0.52%	77
2024 Q2	–	Sell	-40,625	Closed	-$2.85M	–	275
2024 Q1	$2.85M	Sell	40,625 -6,580	-14%	-$509K	0.44%	124
2023 Q4	$3.94M	Buy	+47,205	New	+$1.71M	0.7%	38
2022 Q4	–	Sell	-77,259	Closed	-$3.74M	–	282
2022 Q3	$3.74M	Buy	77,259 +6,457	+9%	+$311K	0.81%	12
2022 Q2	$2.78M	Buy	70,802 +4,547	+7%	+$183K	0.68%	25
2022 Q1	$2.44M	Sell	66,255 -41,743	-39%	-$1.48M	0.45%	73
2021 Q4	$4.92M	Sell	107,998 -2,576	-2%	-$99.4K	0.81%	10
2021 Q3	$3.95M	Buy	+110,574	New	+$3.26M	0.67%	24
2020 Q4	–	Sell	-31,647	Closed	-$685K	–	315
2020 Q3	$685K	Sell	31,647 -93,531	-75%	-$2.19M	0.16%	250
2020 Q2	$2.95M	Buy	+125,178	New	+$2.35M	0.65%	28
2016 Q2	–	Sell	-306,003	Closed	-$2.16M	–	315
2016 Q1	$2.16M	Sell	306,003 -113,469	-27%	-$829K	0.34%	145
2015 Q4	$4.39M	Buy	+419,472	New	+$4.11M	0.57%	25
2013 Q3	–	Sell	-202,465	Closed	-$2.34M	–	328
2013 Q2	$2.34M	Buy	+202,465	New	+$1.59M	0.51%	39

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's CYTK Position: Q2 2026 in Review

EAM Investors opened a new position in Cytokinetics (CYTK) in Q2 2026: 68,185 shares worth $5.81M. The stake represents 0.52% of the portfolio and ranks #77 among its holdings. This is a return to the name: EAM Investors previously reported a position in CYTK as recently as Q1 2024.

EAM Investors first reported a position in CYTK in Q2 2013 and has held it in 13 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

EAM Investors held 68,185 shares of Cytokinetics worth $5.81M as of Q2 2026.
Cytokinetics was a new EAM Investors position in Q2 2026.
Cytokinetics made up 0.52% of EAM Investors's portfolio in Q2 2026, its #77 holding.
EAM Investors first reported a position in Cytokinetics in Q2 2013 and has held it in 13 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.